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Chronic Immunosuppression, Australia Antigenemia, and Hepatitis 
By Thomas E. Starzl and Charles W. Putnam 
MANY early workers in renal trans-plantation noticed a rather high inci-
dence of hepatic dysfunction in their chron-
ically immunosuppressed kidney recipients, 
but there were difficulties in determining 
the etiology of these liver complications. 
The two leading possibilities were hepatitis 
of viral etiology and drug toxicity of the 
agents being administered. With the dis-
covery of the Australia (Au) antigen 
marker by Blumberg, it became possible to 
investigate the whole matter more com-
pletely, and about 1 yr ago we undertook 
a formal study to learn the causes of this 
kind of morbidity. The serologic studies 
were performed by T orisu and have been 
published. 1.2 
From 89 patients who were either ad-
mitted to the hospital or visited the clinic 
for routine follow-up, serum was obtained. 
In addition, stored serum samples taken 
from these patients as long as 5 yr 
previously were available for thawing and 
retrospective serologic examination. The Au 
antigen was looked for in these samples 
with the precipitation methods of detection 
and by the more sensitive technique of 
complement fixation. By one or the other 
methods, there were 23 (26%) of the 89 
recipients whose sera contained the Au 
antigen. In 11 additional patients who had 
abnormal liver function but who were Au 
negative, rabbits were inoculated with a 
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pool of the stored recipient sera. Four of 
the 11 negative pools raised heterologous 
anti-Au antibody after 12-24 wk of im-
munization, indicating that these patients 
had been Au positive but with trace quanti-
ties that were immeasurable with standard 
detection techniques. 
Because of the existence of the stored 
samples of serum, it was possible to find 
out, in many instances, precisely when the 
Au antigenemia developed. Surprisingly, 
about one-half the patients had already 
been Au-antigen positive while on pre-
transplantation dialysis. Inadvertently, they 
had been entered into the transplantation 
program as established serum hepatitis 
carriers. 
The carrier state in the patients with 
preexisting Au antigenemia, as well as in 
those who developed the Au antigen after 
the advent of chronic immunosuppression, 
usually persisted following transplantation. 
Thus, none of our patients in whom the Au 
antigen could be detected by the precipita-
tion methods has ever had disappearance 
of the antigen, and the same has often 
been true when only the complement fixa-
tion tests were positive. Consequently, the 
renal transplant population is a potentially 
dangerous reservoir for the perpetuation of 
serum hepatitis. The disease can be passed 
to the health care personnel. Many of our 
staff members have developed serum hepa-
titis, and one of our transplant research 
technicians died of this disease. 
In the transplant recipients, there was a 
very poor correlation between Au anti-
genemia and the presence of hepatic dys-
function which occurred with almost equal 
frequency in people who were Au negative. 
From these latter observations, it may be 
inferred that hepatitis caused by other 
Transplantation Proceedings, Vol. IV, No.4 (December), 1972 685 
686 
kinds of viruses may play a role in post-
transplantation hepatic disorders or, al-
ternatively, that hepatotoxicity of the im-
munosuppressive agents themselves is a 
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significant factor. In some of our Au nega-
tive patients, we have switched from aza-
thioprine to cyclophosphamide with rever-
sal of serious liver function abnormalities. 
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